【导读】RNA 聚合酶 II 相关蛋白 2（RPAP2）在转录调控中发挥着关键作用。然而，关于 RPAP2 是否以及如何调节肝细胞癌（HCC）细胞生长，以及 RPAP2 ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

该研究开发了一种靶向降解 BCL-xL/BCL-2 的 PROTAC，能够有效清除肝脏中的衰老细胞并减少代谢 功能障碍 相关脂肪性肝炎（MASH）驱动的肝 细胞癌 （HCC）。

*仅供医学专业人士阅读参考虽说奇点糕经常会揪着一些给癌细胞当帮凶的人体免疫细胞，比如巨噬细胞又比如巨噬细胞再比如巨噬细胞来批判，但“惩前毖后，治病救人”的原则，才是看待它们的正确解法。如果能找到导致肿瘤微环境内巨噬细胞作恶的关键点进行干预，双刃剑的朝 ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy ...

In summary, our results indicate that a screening program of 6–12 monthly αFP and liver ultrasound is able to detect smaller and earlier stage tumors in a population at risk of HCC, and result ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...